Cadila Healthcare Limited

Overview

Cadila Healthcare Limited, commonly known as Zydus Cadila, is one of the leading pharmaceutical companies in India. The company is involved in the discovery, development, manufacturing, and marketing of a wide range of healthcare products. Known for its innovative treatments and significant investment in research and development, Zydus Cadila plays a pivotal role in global healthcare.

Therapeutic areas

API / Drug Master Files

Cadila Healthcare Limited holds 0 active (57 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• IMATINIB MESYLATE (AMORPHOUS)Inactive2013-12-18
• ARSENIC TRIOXIDEInactive2013-09-23
• SALMETEROL XINAFOATE USPInactive2012-02-16
• IRBESARTAN USPInactive2011-11-12
• DESVENLAFAXINE BASEInactive2011-10-22
• ERLOTINIB HYDROCHLORIDE (FORM-B)Inactive2011-10-02
• PALIPERIDONEInactive2011-04-30
• ESOMEPRAZOLE SODIUMInactive2011-01-07
• DICLOFENAC EPOLAMINEInactive2011-01-04
• CAPECITABINE USPInactive2011-01-03
• DULOXETINE HYDROCHLORIDE USP (DUB ROUTE)Inactive2010-10-13
• IRINOTECAN HYDROCHLORIDE USPInactive2010-07-20
• SOLIFENACIN SUCCINATEInactive2010-04-05
• CLOPIDOGREL BISULFATE USP (FORM-I) (CUE ROUTE)Inactive2010-01-07
• RANOLAZINEInactive2010-01-06

Showing 15 of 57 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Cadila Healthcare Limited in our records. PharmaTek screens the full directory against live FDA enforcement data.